The research offers hope to tens of thousands of patients with kidney failure who are on a long waiting list for an organ ...

Fintel reports that on February 3, 2025, HC Wainwright & Co. initiated coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a ...

Potent in vivo gene editing in skeletal muscle of non-human primates by a novel, ultracompact CRISPR system delivered via a single AAV vector.

APAC offers stability in an increasing challenging global geopolitical environment for clinical stage drug development.

CRISPR & Cas Genes Market Growing funding in gene therapy worldwide is a prominent factor driving the CRISPR & Cas genes market.

United Therapeutics said the FDA has cleared it to begin the first clinical trial testing whether organs from gene-edited ...

H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Crispr Therapeutics (CRSP) with a Buy rating and $65 price target The firm says ...